[Federal Register Volume 81, Number 121 (Thursday, June 23, 2016)]
[Notices]
[Pages 40889-40890]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-14827]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2016-N-0001]
Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory
Committee; Amendment of Notice
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
amendment to the notice of meeting of the Pediatric Oncology
Subcommittee of the Oncologic Drugs Advisory Committee. This meeting
was announced in the Federal Register of June 16, 2016. The amendment
is being made to reflect a change in the Procedure portion of the
document. There are no other changes.
FOR FURTHER INFORMATION CONTACT: Lauren D. Tesh, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-
796-9001, FAX: 301-847-8533, email: [email protected]; or FDA Advisory
Committee Information Line, 1-800-741-8138 (301-443-0572 in the
Washington, DC area). Please call the Information Line for up-to-date
information on this meeting.
SUPPLEMENTARY INFORMATION: In the Federal Register of June 16, 2016, 81
FR 39274, FDA announced that a meeting of the Pediatric Oncology
Subcommittee of the Oncologic Drugs Advisory Committee would be held on
June 28 and 29, 2016. On page 39274, in the third column, the Procedure
portion of the document is changed to read as follows:
[[Page 40890]]
FDA regrets that it was unable to publish this notice 15 days prior
to the June 28 and 29, 2016, Pediatric Oncology Subcommittee of the
Oncologic Drugs Advisory Committee meeting. Because the Agency believes
there is some urgency to bring these issues to public discussion and
qualified members of the Pediatric Oncology Subcommittee of the
Oncologic Drugs Advisory Committee meeting were available at this time,
the Commissioner of Food and Drugs concluded that it was in the public
interest to hold this meeting even if there was not sufficient time for
the customary 15-day public notice.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.
Dated: June 16, 2016.
Jill Hartzler Warner,
Associate Commissioner for Special Medical Programs.
[FR Doc. 2016-14827 Filed 6-22-16; 8:45 am]
BILLING CODE 4164-01-P